All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What are the main improvements in next-generation CAR T-cell products?
Featured
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Benjamin Derman, University of Chicago, Chicago, US. We asked, What are the main improvements in next-generation chimeric antigen receptor (CAR) T-cell products?
What are the main improvements in next-generation CAR T-cell products?
In this video, Derman considers multiple abstracts1–3 presented at ASH 2022 on studies that aim to improve CAR T-cell products, including the development of CAR T-cell therapies that can interact simultaneously with multiple targets, such as BCMA and CD19. Derman also discusses the possibility of reducing turnaround times by optimizing the manufacturing process, as well as developing CAR T‑cell products that can interact with new targets such as GPRC5D. Improvements in the persistence and immune tolerance of CAR T-cell therapies and initiating therapy in earlier lines are also considered.
- Du J, Fu W, Lu J, et al. Phase I open-label single-arm study of BCMA/CD19 dual-targeting FasTCAR-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma. Oral abstract #366. Presented at: 64th American Society of Hematology Annual Meeting and Exposition; Dec 10, 2022; New Orleans, US.
- Bal S, Kocoglu MH, Nadeem O, et al. Clinical activity of BMS-986393 (CC-95266), a G protein–coupled receptor class C Group 5 member D (GPRC5D)–targeted chimeric antigen receptor (CAR) T cell therapy, in patients with relapsed and/or refractory (R/R) multiple myeloma (MM): First results from a phase 1, multicenter, open-label study. Oral abstract #364. Presented at: 64th American Society of Hematology Annual Meeting and Exposition; Dec 10, 2022; New Orleans, US.
- Megala Costa LJ, Kumar SK, Atrash S, et al. Results from the first phase 1 clinical study of the B-cell maturation antigen (BCMA) NEX T chimeric antigen receptor (CAR) T cell therapy CC-98633/BMS-986354 in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Oral abstract #566. Presented at: 64th American Society of Hematology Annual Meeting and Exposition; Dec 11, 2022; New Orleans, US.
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox